The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Olanzapine and Negative and Positive Symptoms

To the Editor: The article by Alex Kopelowicz, M.D., et al. (1) purported to show that olanzapine helps secondary negative symptoms but not primary negative symptoms. However, there seems to be a confound here. The deficit group (primary negative symptoms) not only failed to show improvement in negative symptoms, but it also showed no improvement in positive symptoms. Those with secondary negative symptoms (the nondeficit group) showed significant improvement in positive and negative symptoms. Therefore, one could explain their results not only by pointing to a differential effect of olanzapine on primary and secondary negative symptoms, but also by asserting that negative symptoms in both groups improve only when positive symptoms improve. I realize that by the authors’ definition, these subjects’ primary negative symptoms did not come from positive symptoms, but that assertion lacks empirical proof.

Reference

1. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J: Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000; 157:987–993LinkGoogle Scholar